Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
1.720
-0.140 (-7.53%)
At close: Jul 18, 2025, 4:00 PM
1.830
+0.110 (6.40%)
After-hours: Jul 18, 2025, 7:36 PM EDT
CNTB Revenue
Connect Biopharma Holdings had revenue of $1.92M in the half year ending December 31, 2024. This brings the company's revenue in the last twelve months to $26.03M. In the year 2024, Connect Biopharma Holdings had annual revenue of $26.03M.
Revenue (ttm)
$26.03M
Revenue Growth
n/a
P/S Ratio
3.65
Revenue / Employee
$419,887
Employees
62
Market Cap
95.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CNTB News
- 15 hours ago - Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire
- 1 day ago - Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 5 weeks ago - Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress - GlobeNewsWire
- 6 weeks ago - Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress - GlobeNewsWire
- 7 weeks ago - Connect Biopharma to Present at Two Upcoming Investor Conferences in June - GlobeNewsWire
- 2 months ago - Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference - GlobeNewsWire
- 2 months ago - Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD - GlobeNewsWire